The endocannabinoid system (ECS) is a widespread neurotransmitter system. A key characteristic of the ECS is that there are multiple endogenous ligands (endocannabinoids). Of these, the most extensively studied are arachidonoyl ethanolamide (AEA) and 2-arachidonoyl-glycerol (2-AG), both act as agonists at the cannabinoid CB1 receptor. In humans, three CB1 variants have been identified: hCB1, considered the most abundant G protein-coupled receptor in the brain, alongside the less abundant and studied variants, hCB1a and hCB1b. CB1 exhibits a preference for coupling with inhibitory Gi/o proteins, although its interactions with specific members of the Gi/o family remain poorly characterized. This study aimed to compare the AEA and 2-AG-induced activation of various G protein subtypes at CB1. Furthermore, we compared the response of human CB1 (hCB1, hCB1a, hCB1b) and explored species differences by examining rodent receptors (mCB1, rCB1).
Materials and Methods:
Activation of individual G protein subtypes in HEK293 cells transiently expressing CB1 was measured with G protein dissociation assay utilizing TRUPATH biosensors. The performance of the TRUPATH biosensors was evaluated using Z-factor analysis. Pathway potencies and efficacies were analyzed using the operational analysis of bias to determine G protein subtype selectivity for AEA and 2-AG.
Results:
Initial screening of TRUPATH biosensors performance revealed variable sensitivities within our system. Based on the biosensor performance, the G protein subtypes pursued for further characterization were Gi1, Gi3, GoA, GoB, GZ, G12, and G13. Across all pathways, AEA demonstrated partial agonism, whereas 2-AG exhibited full or high-efficacy agonism. Notably, we provide direct evidence that the hCB1 receptor couples to G12 and G13 proteins. Our findings do not indicate any evidence of G protein subtype selectivity. Similar observations were made across the human receptor variants (hCB1, hCB1a, hCB1b), as well as at mCB1 and rCB1.
Discussion:
There was no evidence suggesting G protein subtype selectivity for AEA and 2-AG at CB1, and this finding remained consistent across human receptor variants and different species.
Get full access to this article
View all access options for this article.
References
1.
ZouS, KumarU. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci, 2018; 19(3):833; doi: 10.3390/ijms19030833
2.
Di MarzoV, De PetrocellisL. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci, 2012; 367(1607):3216–3228; doi: 10.1098/rstb.2011.0382
3.
DevaneWA, HanusL, BreuerA, et al.Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992; 258(5090):1946–1949; doi: 10.1126/science.1470919
4.
MechoulamR, Ben-ShabatS, HanusL, et al.Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol, 1995; 50(1):83–90; doi: 10.1016/0006-2952(95)00109-D
5.
SugiuraT, KondoS, SukagawaA, et al.2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun, 1995; 215(1):89–97; doi: 10.1006/bbrc.1995.2437
6.
HerkenhamM, LynnAB, LittleMD, et al.Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990; 87(5):1932–1936.
7.
MatsudaLA, LolaitSJ, BrownsteinMJ, et al.Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990; 346(6284):561–564; doi: 10.1038/346561a0
8.
ShireD, CarillonC, KaghadM, et al.An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem, 1995; 270(8):3726–3731; doi: 10.1074/jbc.270.8.3726
9.
RybergE, VuHK, LarssonN, et al.Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett, 2005; 579(1):259–264; doi: j.febslet.2004.11.085
10.
XiaoJC, JewellJP, LinLS, et al.Similar in vitro pharmacology of human cannabinoid CB1 receptor variants expressed in CHO cells. Brain Res, 2008; 1238:36–43; doi: 10.1016/j.brainres.2008.08.027
11.
González-MariscalI, Krzysik-WalkerSM, DoyleME, et al.Human CB1 receptor isoforms, present in hepatocytes and β-cells, are involved in regulating metabolism. Sci Rep, 2016; 6(1):33302; doi: 10.1038/srep33302
12.
BagherAM, LaprairieRB, KellyMEM, et al.Co-expression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes. Eur J Pharmacol, 2013; 721(1–3):341–354; doi: 10.1016/j.ejphar.2013.09.002
13.
Rinaldi-CarmonaM, CalandraB, ShireD, et al.Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther, 1996; 278(2):871–878.
14.
StraikerA, Wager‐MillerJ, HutchensJ, et al.Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones. Br J Pharmacol, 2012; 165(8):2660–2671; doi: j.1476-5381.2011.01744.x
15.
ChakrabartiA, OnaiviES, ChaudhuriG. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Seq, 1995; 5(6):385–388; doi: 10.3109/10425179509020870
16.
AboodME. Molecular Biology of Cannabinoid Receptors. In: PertweeRG., editor. Cannabinoids. Berlin, Heidelberg: Springer Berlin Heidelberg; 2005. p. 81–115.doi:10.1007/3-540-26573-2_3
17.
SyrovatkinaV, AlegreKO, DeyR, et al.Regulation, signaling, and physiological functions of G-proteins. J Mol Biol, 2016; 428(19):3850–3868; doi: 10.1016/j.jmb.2016.08.002
18.
HowlettA, QualyJM, KhachatrianLL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol, 1986; 29(3):307–313.
19.
GlassM, FelderCC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci, 1997; 17(14):5327–5333; doi: 10.1523/JNEUROSCI.17-14-05327.1997
20.
BonhausD, ChangL, KwanJ, et al.Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther, 1998; 287(3):884–888.
21.
FelderCC, JoyceKE, BrileyEM, et al.LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther, 1998; 284(1):291–297.
22.
KearnCS, Blake-PalmerK, DanielE, et al.Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol, 2005; 67(5):1697–1704.
23.
FinlayDB, CawstonEE, GrimseyNL, et al.Gαs signalling of the CB1 receptor and the influence of receptor number. Br J Pharmacol, 2017; 174(15):2545–2562; doi: 10.1111/bph.13866
24.
CalandraB, PortierM, KernéisA, et al.Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol, 1999; 374(3):445–455; doi: 10.1016/S0014-2999(99)00349-0
25.
LaucknerJE, HilleB, MackieK. The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A, 2005; 102(52):19144–19149; doi: 10.1073/pnas.0509588102
26.
McIntoshB, HudsonB, YegorovaS, et al.Agonist‐dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol, 2007; 152(7):1111–1120; doi: 10.1038/sj.bjp.0707495
27.
RolandAB, RicobarazaA, CarrelD, et al.Cannabinoid-induced actomyosin contractility shapes neuronal morphology and growth. Elife, 2014; 3:e03159; doi: 10.7554/eLife.03159
28.
IshiiI, ChunJ. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. Neuroreport, 2002; 13(5):593–596; doi: 10.1097/00001756-200204160-00011
29.
GlennNAK, FinlayDB, CarruthersER, et al.RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB(1), CB(2), GPR18 and GPR55 cannabinoid receptors. Br J Pharmacol, 2023; 181(14):2212–2231; doi: 10.1111/bph.16095
30.
AvetC, ManciniA, BretonB, et al.Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs. Elife, 2022; 11; doi: 10.7554/eLife.74101
GlassM, NorthupJK. Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol Pharmacol, 1999; 56(6):1362–1369; doi: 10.1124/mol.56.6.1362
LaprairieRB, BagherAM, KellyME, et al.Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol Pharmacol, 2016; 89(3):364–375; doi: 10.1124/mol.115.101980
36.
Diez-AlarciaR, Ibarra-LecueI, Lopez-CardonaÁP, et al.Biased agonism of three different cannabinoid receptor agonists in mouse brain cortex. Front Pharmacol, 2016; 7:415; doi: 10.3389/fphar.2016.00415
37.
KolbP, KenakinT, AlexanderSPH, et al.Community guidelines for GPCR ligand bias: IUPHAR review 32. Br J Pharmacol, 2022; 179(14):3651–3674; doi: 10.1111/bph.15811
38.
KenakinT, WatsonC, Muniz-MedinaV, et al.A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci, 2012; 3(3):193–203.
39.
van der WesthuizenET, BretonB, ChristopoulosA, et al.Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol, 2014; 85(3):492–509; doi: 10.1124/mol.113.088880
40.
ZhuX, FinlayDB, GlassM, et al.An evaluation of the operational model when applied to quantify functional selectivity. Br J Pharmacol, 2018; 175(10):1654–1668; doi: 10.1111/bph.14171
41.
OlsenRHJ, DiBertoJF, EnglishJG, et al.TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat Chem Biol, 2020; 16(8):841–849; doi: 10.1038/s41589-020-0535-8
42.
RyallsB, PatelM, SparkesE, et al.Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor. Biochem Pharmacol, 2024; 222:116052; doi: 10.1016/j.bcp.2024.116052
43.
FinlayDB, ManningJJ, IbsenMS, et al.Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chem Neurosci, 2019; 10(10):4350–4360; doi: 10.1021/acschemneuro.9b00429
44.
ZhangJ-H, ChungTD, OldenburgKR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen, 1999; 4(2):67–73.
45.
OnoY, KawakamiK, NakamuraG, et al.Generation of Gαi knock-out HEK293 cells illuminates Gαi-coupling diversity of GPCRs. Commun Biol, 2023; 6(1):112.
46.
AtwoodBK, LopezJ, Wager-MillerJ, et al.Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics, 2011; 12:14.
47.
TennakoonM, SenarathK, KankanamgeD, et al.Subtype-dependent regulation of Gβγ signalling. Cell Signal, 2021; 82:109947; doi: 10.1016/j.cellsig.2021.109947
48.
YimYY, BetkeKM, McDonaldWH, et al.The in vivo specificity of synaptic Gβ and Gγ subunits to the α2a adrenergic receptor at CNS synapses. Sci Rep, 2019; 9(1):1718; doi: 10.1038/s41598-018-37222-1
49.
RysiewiczB, BłasiakE, MystekP, et al.Beyond the G protein α subunit: investigating the functional impact of other components of the Gαi3 heterotrimers. Cell Commun Signal, 2023; 21(1):279; doi: 10.1186/s12964-023-01307-w
50.
MystekP, RysiewiczB, GregrowiczJ, et al.Gγ and Gα identity dictate a G-protein heterotrimer plasma membrane targeting. Cells, 2019; 8(10):1246; doi: 10.3390/cells8101246
51.
MasuhoI, SkamangasNK, MunteanBS, et al.Diversity of the Gβγ complexes defines spatial and temporal bias of GPCR signaling. Cell Syst, 2021; 12(4):324–337.e5; doi: 10.1016/j.cels.2021.02.001
52.
FarrellJS, ColangeliR, DongA, et al.In vivo endocannabinoid dynamics at the timescale of physiological and pathological neural activity. Neuron, 2021; 109(15):2398–2403.e4; doi: 10.1016/j.neuron.2021.05.026
53.
WeiD, AllsopS, TyeK, et al.Endocannabinoid signaling in the control of social behavior. Trends Neurosci, 2017; 40(7):385–396; doi: 10.1016/j.tins.2017.04.005
54.
LuchicchiA, PistisM. Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol, 2012; 46(2):374–392; doi: 10.1007/s12035-012-8299-0
55.
AgasidMT, SørensenL, UrnerLH, et al.The Effects of Sodium Ions on Ligand Binding and Conformational States of G Protein-Coupled Receptors—Insights from Mass Spectrometry. J Am Chem Soc, 2021; 143(11):4085–4089.
56.
SugiuraT, KodakaT, KondoS, et al.Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma× glioma hybrid NG108-15 cells. Biochem Biophys Res Commun, 1997; 233(1):207–210; doi: 10.1006/bbrc.1997.6425
57.
KenakinT, MillerLJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev, 2010; 62(2):265–304.
58.
McPartlandJ, GlassM, PertweeR. Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol, 2007; 152(5):583–593.
59.
FinlayDB. Factors Influencing the Specificity and Bias of CB1 Cannabinoid Receptor Signalling: University of Auckland; 2018.
60.
Wager-MillerJ, WestenbroekR, MackieK. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids, 2002; 121(1–2):83–89; doi: 10.1016/s0009-3084(02)00151-2
RiosC, GomesI, DeviLA. μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol, 2006; 148(4):387–395; doi: 10.1038/sj.bjp.0706757
63.
CarribaP, OrtizO, PatkarK, et al.Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology, 2007; 32(11):2249–2259; doi: 10.1038/sj.npp.1301375
64.
HilairetS, BouaboulaM, CarrièreD, et al.Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem, 2003; 278(26):23731–23737; doi: 10.1074/jbc.M212369200
65.
EllisJ, PedianiJD, CanalsM, et al.Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and-independent coordinated alterations of receptor localization and function. J Biol Chem, 2006; 281(50):38812–38824; doi: 10.1074/jbc.M602494200
66.
BreivogelCS, SelleyDE, ChildersSR. Cannabinoid receptor agonist efficacy for stimulating [35S] GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem, 1998; 273(27):16865–16873.
67.
KearnCS, GreenbergMJ, DiCamelliR, et al.Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem, 1999; 72(6):2379–2387.
68.
VogelZ, BargJ, LevyR, et al.Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem, 1993; 61(1):352–355.
69.
ChildersSR, SextonT, RoyMB. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol, 1994; 47(4):711–715.
70.
MackieK, DevaneWA, HilleB. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol, 1993; 44(3):498–503.
71.
HillardCJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat, 2000; 61(1–2):3–18.
72.
SavinainenJR, JärvinenT, LaineK, et al.Despite substantial degradation, 2‐arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor‐dependent G‐protein activation in rat cerebellar membranes. Br J Pharmacol, 2001; 134(3):664–672.
73.
StellaN, SchweitzerP, PiomelliD. A second endogenous cannabinoid that modulates long-term potentiation. Nature, 1997; 388(6644):773–778; doi: 10.1038/42015
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
